This's week's top news includes T cell receptor immunotherapy against a novel target and Recce Pharmaceuticals’ synthetic approach to combatting AMR

📈 Trending news from the industry

'A T cell receptor immunotherapy against a novel target'

In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers. Read the full article here.

'Recce Pharmaceuticals’ synthetic approach to combatting AMR'

Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a synthetic polymer designed to target a variety of infections caused by even the most difficult-to-treat bacteria, including their mutated forms. Discover more...

'The promise of vectors targeting the LDL receptor'

Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, answers your questions, by outlining the potential of RNA interference therapeutics and the challenges of their use in vivo. Read the interview here.

'Mitigating fibrotic barriers in pancreatic cancer'

A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery. Discover more...

'Proteogenomics: finding targets for never-smoker lung cancer'

Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases. Read more here.

📘 What to read

Introducing our brand-new eBook: Drop by drop: the future of liquid biopsy

What's inside this eBook:

 🔬Chapter 1: Liquid Biopsy and Cancer – Learn how this technology is changing cancer detection and treatment.

🔬Chapter 2: Neuroscience Applications – Explore the potential of liquid biopsy in diagnosing and treating neurological conditions.

🔬Chapter 3: Rare Diseases – Understand the role of liquid biopsy in the early detection and management of rare diseases.

DOWNLOAD TODAY!

🎧 Listen up!

'Exploring the wonders of molecular biology'

Bringing their expertise, we are thrilled to introduce our speakers Dr Matthew Nelson, and Dr Jake Rubens.

Key discussion points:

• DNA has been called the code of life. How much of this code have we deciphered?
• How is technology evolving to allow us to better understand the consequences of genetic changes (DNA mutations, epigenetics, etc.) and health and disease? What impact do we expect this to have in drug discovery?
• How do we go from sequencing the DNA of individuals to making connections to health and disease? What are some examples of gene-disease links we’ve made that have informed drug target selection?

Download the episode here!

Sign up for free! 🖊️

Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.

Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.